U.S. Markets closed

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
7.43+0.06 (+0.81%)
At close: 4:00PM EST

RedHill Biopharma Ltd.

21 Ha’arba’a Street
Tel Aviv 6473921
972 3 541 3131

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees155

Key Executives

NameTitlePayExercisedYear Born
Mr. Dror Ben-AsherCo-Founder, Chairman & CEO448.42kN/A1966
Mr. Micha Ben-ChorinChief Financial Officer339.01kN/A1969
Mr. Gilead RadayChief Operating Officer361.68kN/A1975
Mr. Adi FrishChief Corp. & Bus. Devel. Officer338.12kN/A1970
Mr. Guy GoldbergChief Bus. Officer338.13kN/A1976
Dr. June S. AlmenoffChief Scientific OfficerN/AN/A1957
Mr. Ben MartieVP, Legal AffairsN/AN/AN/A
Ms. Shani MauriceVP of Bus. Devel. & CommunicationsN/AN/AN/A
Ms. Valerie GraceffaVP of SalesN/AN/AN/A
Mr. Rob JacksonSr. VP of Sales & MarketingN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focused on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, with a planned Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), a SK2 selective inhibitor targeting various indications with a Phase 2/3 program for COVID-19 and Phase 2 studies for prostate cancer and cholangiocarcinoma ongoing; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and in Phase 2 studies for irritable bowel syndrome with diarrhea; RHB-107, a Phase 2-stage serine protease inhibitor for cancer and inflammatory gastrointestinal diseases, and is also being evaluated for COVID-19; and RHB-106, an encapsulated bowel preparation. The company was founded in 2009 and is headquartered in Tel Aviv, Israel.

Corporate Governance

RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.